drugset / Trial / NCT00016419
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome
Phase 2
Completed
130 enrolled
SWOG Cancer Research Network
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be an effective treatment for myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of antithymocyte globulin plus cyclosporine in treating patients who have myelodysplastic syndrome.
Timeline
- Start
- 2001-08
- Primary completion
- 2003-07
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 3.5 mg/kg | Intravenous |
| Subject | Cyclosporine | Peptide | 3 mg/kg | Oral |